首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

2016157

血漿分餾市場報告：按產品、產業、應用、最終用戶和地區分類（2026-2034 年）

Plasma Fractionation Market Report by Product, Sector, Application, End User, and Region 2026-2034

出版日期: 2026年04月01日 | 出版商:

IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2025年全球血漿分餾市場規模達277億美元。展望未來，預計到2034年該市場規模將達到423億美元，2026年至2034年的複合年成長率為4.67%。慢性病盛行率上升、技術進步以及醫療保健領域投資增加是推動市場成長的主要因素。

血漿分餾市場的發展趨勢：

人口老化的過程

隨著人口老化，老年人更容易出現各種健康問題，包括免疫力缺乏、神經系統疾病和慢性病，因此對血漿療法的需求日益成長。例如，世界衛生組織（WHO）的報導預測，到2030年，全球六分之一的人口將超過60歲。此外，預計到2050年，全球60歲以上人口將達到約21億人。另外，根據美國國家醫學圖書館（NLM）的報告，印度約有21%的老年人患有至少一種慢性病。高血壓和糖尿病約佔所有慢性病的68%。源自血漿分餾的血漿療法對於有效治療許多此類疾病至關重要。這些治療方法在控制症狀和提高生活品質方面發揮關鍵作用。這些因素正在推動血漿分餾市場佔有率的擴大。

罕見慢性病盛行率

罕見慢性病盛行率的上升是市場成長的主要驅動力。例如，根據美國食品藥物管理局(FDA) 2022 年 12 月發表的報導，美國有超過 3,000 萬人患有 7,000 多種罕見疾病。此外，許多罕見慢性病需要專門的治療，包括血漿分餾衍生治療方法。這些治療方法對於控制症狀、提高生活品質和提供挽救生命的干涉措施至關重要。例如，根據印度投資局 (Invest India) 發表的報導，血漿分餾具有多種治療應用，包括治療先天性或免疫不全症、創傷後恢復血容量以及高效去活化 HIV 和肝炎病毒等病毒污染物。此外，新的血漿衍生產品獲得監管部門核准以及適應症的擴大也促進了市場成長，使更多患者能夠獲得這些治療。例如，2024 年 6 月，武田製藥公司宣布，日本厚生勞動省已批准將「CUVITRU」用作 2 歲及以上無丙種球蛋白血症或免疫力缺乏患者的替代療法，這些患者的抗體水平極低或續發性，並且由於原發性免疫力缺乏(PID) 或繼發性免疫缺陷 (SID) 而有嚴重核准性行為感染的風險增加。

煉油技術的進步

純化技術的進步顯著提高了血漿製品的品質、安全性和療效。其中一項最重要的進步在於病毒去活化和去除方法的改進。溶劑和界面活性劑處理、巴氏殺菌和奈米過濾等技術的進步，使得在有效去除病毒的同時保留血漿製品中的治療性蛋白質成為可能。這確保了更高的安全標準，並降低了病毒感染的風險。例如，根據美國國家醫學圖書館發表的一篇論文，人體血清蛋白、凝血因子、免疫球蛋白和酵素抑制劑等治療性血漿蛋白需在60 度C下加熱處理10小時，以去活化血液傳播病毒。此外，親和層析法和離子交換層析法等先進的層析法技術，能夠根據血漿蛋白的特性進行更精確的分離，從而改進了純化過程。這提高了免疫球蛋白、白蛋白和凝血因子等治療性蛋白質的純度和產量。例如，2023年11月，總部位於美國的生命科學公司Cytiva宣布推出其「Cytiva Protein Select」技術，可簡化並加速重組蛋白的純化過程。自切割、無痕標籤與親和性層析法結合，使所有蛋白質的純化過程標準化，無需使用蛋白質親和性親和結合配體。

The global plasma fractionation market size reached USD 27.7 Billion in 2025. Looking forward, the market is expected to reach USD 42.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.67% during 2026-2034. The rising prevalence of chronic diseases, technological advancements, and the increasing investment in healthcare are some of the major factors driving the market growth.

PLASMA FRACTIONATION MARKET ANALYSIS:

Major Market Drivers: The rising need for preventing, managing, and treating infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune diseases is driving the market growth.
Key Market Trends: Key players across countries are investing in R&D activities to enhance plasma production technology for product efficacy and recovery of immunoglobulin G (IgG) to isolate new plasma proteins, which is one of the emerging trends bolstering the market.
Competitive Landscape: Some of the prominent companies in the market include ADMA Biologics Inc., Boccard, CSL, Grifols, S.A., Intas Pharmaceuticals Ltd., Kedrion, LFB, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., and Sartorius AG, among many others.
Geographical Trends: North America currently dominates the global market due to the region's advanced healthcare infrastructures, high demand for plasma-derived products, and the development of affordable viral inactivation and processing technologies.
Challenges and Opportunities: One of the primary challenges hindering the market is the growing concerns over ensuring a stable and sufficient supply of plasma. However, the increasing donor recruitment efforts are expected to fuel the market in the coming years.

PLASMA FRACTIONATION MARKET TRENDS:

Rising Geriatric Population

As people age, they are more prone to various health conditions, such as immune deficiencies, neurological disorders, and chronic diseases, thereby propelling the need for plasma products. For instance, according to an article published by the World Health Organization (WHO), by 2030, one in every six persons in the world will be 60 or older. Moreover, the global population of individuals aged 60 and above will be approximately 2.1 billion by 2050. Besides this, as per the National Library of Medicine, about 21% of the elderly in India suffer from at least one chronic condition. Hypertension and diabetes are responsible for approximately 68% of all chronic illnesses. Plasma products derived from fractionation are essential for treating many of these conditions effectively. These therapies play a crucial role in managing symptoms and improving the quality of life in these cases. These factors are contributing to the plasma fractionation market share.

Prevalence of Rare Chronic Diseases

The rising prevalence of rare chronic diseases is significantly driving the growth of the market. For instance, according to an article published by the Food & Drug Administration (FDA) in December 2022, more than 30 million people suffer from more than 7,000 rare diseases in the U.S. Moreover, many rare chronic diseases require specialized treatments, including therapies derived from plasma fractionation. These treatments are essential for managing symptoms, improving quality of life and providing life-saving interventions. For instance, according to an article published by Invest India, there are many therapeutic applications for plasma fractionation, such as the treatment of congenital or immunological deficiency diseases, trauma blood volume restoration, and the very efficient inactivation of viral contaminants like HIV and hepatitis viruses. Besides this, regulatory approvals for new plasma-derived products and expanding indications also stimulate market growth, allowing more patients access to these treatments. For example, in June 2024, Takeda announced that the Ministry of Health, Labour, and Welfare in Japan approved the use of CUVITRU as replacement therapy for patients aged two years and older with agammaglobulinemia or hypogammaglobulinemia disorders characterized by extremely low or absent antibody levels and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID).

Advancements in Purification Techniques

Advancements in purification techniques have significantly enhanced the quality, safety, and efficiency of plasma-derived products. One of the most critical advancements is in the methods of viral inactivation and removal. Techniques, such as solvent/detergent treatment, pasteurization, and nanofiltration, have been refined to effectively eliminate viruses while preserving therapeutic proteins in plasma products. This ensures higher safety standards and reduces the risk of viral transmission. For instance, according to an article published by the National Library of Medicine, therapeutic plasma proteins, including human albumin, coagulation factors, immunoglobulins, and enzyme inhibitors, are pasteurized at 60°C for 10 hours to kill blood-borne viruses of concern. Moreover, modern chromatographic techniques, including affinity chromatography and ion exchange chromatography, have improved the purification process by allowing for more precise separation of plasma proteins based on their specific characteristics. This results in higher purity and yield of therapeutic proteins like immunoglobulins, albumin, and clotting factors. For instance, in November 2023, Cytiva, one of the life science companies headquartered in the United States, launched the Cytiva Protein Select technology, which streamlines and accelerates recombinant protein purification. The self-cleaving traceless tag and complementary affinity chromatography resin standardize purification for any protein, thereby eliminating the need for protein-specific affinity binding partners.

GLOBAL PLASMA FRACTIONATION INDUSTRY SEGMENTATION:

Breakup by Product:

Immunoglobulins
Albumin
Coagulation factor VIII
Coagulation factor IX

Immunoglobulins currently exhibit a clear dominance in the market

Immunoglobulins, also known as antibodies, play a dominant role in plasma fractionation due to their widespread therapeutic applications and high demand. Immunoglobulins are used to treat various medical conditions, including primary and secondary immunodeficiencies, autoimmune diseases, inflammatory disorders, and neurological diseases. They are essential for boosting immune function and managing symptoms in patients with these conditions. For instance, in September 2022, Grifols, one of the plasma medicines providers, signed a long-term agreement with Canada's national blood authority to increase the country's self-sufficiency in immunoglobulin significantly (Ig) medicines that are used to treat a variety of immunodeficiencies and other medical conditions.

Breakup by Sector:

Private Sector
Public Sector

Private sector accounts for the majority of the total market share

In the private sector, plasma fractionation plays a crucial role in producing essential plasma-derived therapies, which are vital for treating various medical conditions, such as immunodeficiencies, hemophilia, and autoimmune disorders. Private companies are pivotal in advancing the fractionation process through investment in cutting-edge technologies and infrastructure, ensuring high-quality and efficient production. They also drive innovation by developing new therapeutic products and improving existing ones, thereby expanding treatment options for patients. Additionally, the private sector contributes significantly to the global plasma supply chain, enhancing the availability of these life-saving therapies. Through strategic partnerships and robust distribution networks, private companies facilitate the timely delivery of plasma-derived products to healthcare providers and patients worldwide, underscoring their indispensable role in the healthcare ecosystem.

Breakup by Application:

Neurology
Immunology
Hematology
Other Applications

Neurology currently holds the largest market share

Neurology represented the largest segment in the market due to the high demand for plasma-derived therapies in treating neurological disorders. Conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome, and multifocal motor neuropathy, require immunoglobulins derived from plasma for effective management. For example, intravenous immunoglobulin (IVIG) therapy, which is critical in treating CIDP, helps reduce inflammation and improve muscle strength and function in patients. The prevalence of such neurological conditions and the effectiveness of plasma-derived therapies in their treatment drive significant demand in this segment, highlighting the critical role of plasma fractionation in neurology.

Breakup by End User:

Hospitals and Clinics
Clinical Research Laboratories
Academic Institutes

Hospitals and clinics exhibit a clear dominance in the market

Hospitals and clinics accounted for the largest market share, as they are the primary end-users of plasma-derived therapies, which are essential for treating a wide range of medical conditions. These healthcare facilities frequently administer treatments like intravenous immunoglobulins (IVIG) for immune deficiencies, albumin for hypovolemia, and clotting factors for hemophilia patients. For instance, in cases of severe trauma or surgery, hospitals rely on albumin to restore blood volume and stabilize patients. The constant need for such critical therapies in acute care settings underscores the substantial demand from hospitals and clinics, making them the largest consumers in the plasma fractionation market. Their pivotal role in delivering comprehensive patient care drives the growth and prominence of this segment.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America exhibits a clear dominance

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, particularly the United States, boasts advanced healthcare infrastructure with a well-established network of hospitals, clinics, and specialized treatment centers. This infrastructure supports the extensive use and distribution of plasma-derived therapies. Moreover, the region has a high demand for plasma-derived products due to a large patient population requiring treatments for various medical conditions, such as immunodeficiencies, hemophilia, autoimmune diseases, and neurological disorders. For instance, in March 2021, BPL sold 25 Grifols plasma facilities in the United States, resulting in an additional one million liters for plasma fractionation. Thus, such activities by leading industry players are expected to fuel market growth over the forecasted period.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major plasma fractionation companies have also been provided. Some of the key players in the market include:

ADMA Biologics Inc.
Boccard
CSL
Grifols, S.A.
Intas Pharmaceuticals Ltd.
Kedrion
LFB
Octapharma AG
PlasmaGen BioSciences Pvt. Ltd.
Sartorius AG

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global plasma fractionation market in 2025?

2. What is the expected growth rate of the global plasma fractionation market during 2026-2034?

3. What has been the impact of COVID-19 on the global plasma fractionation market?

4. What are the key factors driving the global plasma fractionation market?

5. What is the breakup of the global plasma fractionation market based on the product?

6. What is the breakup of the global plasma fractionation market based on the sector?

7. What is the breakup of the global plasma fractionation market based on the application?

8. What is the breakup of the global plasma fractionation market based on the end user?

9. What are the key regions in the global plasma fractionation market?

10. Who are the key players/companies in the global plasma fractionation market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Plasma Fractionation Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Immunoglobulins
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Albumin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Coagulation factor VIII
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Coagulation factor IX
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Sector

7.1 Private Sector
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Public Sector
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Application

8.1 Neurology
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Immunology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Hematology
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Other Applications
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals and Clinics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Clinical Research Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Academic Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 ADMA Biologics Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Boccard
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 CSL
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Grifols, S.A.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Intas Pharmaceuticals Ltd.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
- 15.3.6 Kedrion
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 LFB
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
- 15.3.8 Octapharma AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 SWOT Analysis
- 15.3.9 PlasmaGen BioSciences Pvt. Ltd.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
- 15.3.10 Sartorius AG
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Plasma Fractionation Market: Major Drivers and Challenges
Figure 2: Global: Plasma Fractionation Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Plasma Fractionation Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Plasma Fractionation Market: Breakup by Product (in %), 2025
Figure 5: Global: Plasma Fractionation Market: Breakup by Sector (in %), 2025
Figure 6: Global: Plasma Fractionation Market: Breakup by Application (in %), 2025
Figure 7: Global: Plasma Fractionation Market: Breakup by End User (in %), 2025
Figure 8: Global: Plasma Fractionation Market: Breakup by Region (in %), 2025
Figure 9: Global: Plasma Fractionation (Immunoglobulins) Market: Sales Value (in Million USD), 2020 & 2025
Figure 10: Global: Plasma Fractionation (Immunoglobulins) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 11: Global: Plasma Fractionation (Albumin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 12: Global: Plasma Fractionation (Albumin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 13: Global: Plasma Fractionation (Coagulation factor VIII) Market: Sales Value (in Million USD), 2020 & 2025
Figure 14: Global: Plasma Fractionation (Coagulation factor VIII) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 15: Global: Plasma Fractionation (Coagulation factor IX) Market: Sales Value (in Million USD), 2020 & 2025
Figure 16: Global: Plasma Fractionation (Coagulation factor IX) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 17: Global: Plasma Fractionation (Private Sector) Market: Sales Value (in Million USD), 2020 & 2025
Figure 18: Global: Plasma Fractionation (Private Sector) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 19: Global: Plasma Fractionation (Public Sector) Market: Sales Value (in Million USD), 2020 & 2025
Figure 20: Global: Plasma Fractionation (Public Sector) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 21: Global: Plasma Fractionation (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
Figure 22: Global: Plasma Fractionation (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 23: Global: Plasma Fractionation (Immunology) Market: Sales Value (in Million USD), 2020 & 2025
Figure 24: Global: Plasma Fractionation (Immunology) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 25: Global: Plasma Fractionation (Hematology) Market: Sales Value (in Million USD), 2020 & 2025
Figure 26: Global: Plasma Fractionation (Hematology) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 27: Global: Plasma Fractionation (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
Figure 28: Global: Plasma Fractionation (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 29: Global: Plasma Fractionation (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
Figure 30: Global: Plasma Fractionation (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 31: Global: Plasma Fractionation (Clinical Research Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
Figure 32: Global: Plasma Fractionation (Clinical Research Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 33: Global: Plasma Fractionation (Academic Institutes) Market: Sales Value (in Million USD), 2020 & 2025
Figure 34: Global: Plasma Fractionation (Academic Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 35: North America: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 36: North America: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 37: United States: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 38: United States: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 39: Canada: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 40: Canada: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 41: Asia-Pacific: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 42: Asia-Pacific: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 43: China: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 44: China: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 45: Japan: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 46: Japan: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 47: India: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 48: India: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 49: South Korea: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 50: South Korea: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 51: Australia: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 52: Australia: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 53: Indonesia: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 54: Indonesia: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 55: Others: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 56: Others: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 57: Europe: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 58: Europe: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 59: Germany: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 60: Germany: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 61: France: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 62: France: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 63: United Kingdom: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 64: United Kingdom: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 65: Italy: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 66: Italy: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 67: Spain: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 68: Spain: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 69: Russia: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 70: Russia: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 71: Others: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 72: Others: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 73: Latin America: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 74: Latin America: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 75: Brazil: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 76: Brazil: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 77: Mexico: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 78: Mexico: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 79: Others: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 80: Others: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 81: Middle East and Africa: Plasma Fractionation Market: Sales Value (in Million USD), 2020 & 2025
Figure 82: Middle East and Africa: Plasma Fractionation Market: Breakup by Country (in %), 2025
Figure 83: Middle East and Africa: Plasma Fractionation Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 84: Global: Plasma Fractionation Industry: SWOT Analysis
Figure 85: Global: Plasma Fractionation Industry: Value Chain Analysis
Figure 86: Global: Plasma Fractionation Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Plasma Fractionation Market: Key Industry Highlights, 2025 & 2034
Table 2: Global: Plasma Fractionation Market Forecast: Breakup by Product (in Million USD), 2026-2034
Table 3: Global: Plasma Fractionation Market Forecast: Breakup by Sector (in Million USD), 2026-2034
Table 4: Global: Plasma Fractionation Market Forecast: Breakup by Application (in Million USD), 2026-2034
Table 5: Global: Plasma Fractionation Market Forecast: Breakup by End User (in Million USD), 2026-2034
Table 6: Global: Plasma Fractionation Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 7: Global: Plasma Fractionation Market: Competitive Structure
Table 8: Global: Plasma Fractionation Market: Key Players

02-2729-4219

+886-2-2729-4219